The early stages of biotech drug development are often described as a "valley of death" due to funding challenges. However, there is a shift underway as more U.S. federal grants and family offices enter the sector, altering traditional investment strategies.
A recent analysis covering 2024 and 2025 found that 38% of seed-stage biotech companies plan to make nondilutive funding—financing that does not require giving up equity—a core strategy. This trend corresponds with the passage of the latest U.S. budget, which provides significant financial incentives for life sciences companies.
According to a blog post cited in the report, family offices “are emerging as influential investors in the early-stage life sciences sector,” noting their generous capital mandates.
Ram May-Ron, managing partner at FreeMind Group, highlighted the expanding opportunities for nondilutive funding: “Nondilutive funding for life sciences companies is a ‘huge and untapped’ market and now is an ‘incredible time’ for the landscape because the long-delayed U.S. federal budget has finally been signed.” FreeMind helps life science organizations secure such funds from U.S. agencies and private foundations.
The budget approved by President Trump on February 4 increases National Institutes of Health (NIH) funding to approximately $49 billion, nearly doubles the Congressionally Directed Medical Research Programs budget to about $1.3 billion, and allocates $1.5 billion for the Advanced Research Projects Agency for Health, according to May-Ron.
This marks the first fully approved U.S. budget since October 2023. While initial proposals faced cuts, final allocations reflect an industry shift toward expanded nondilutive funding options.
May-Ron noted that although roughly $1.3 billion is allocated for the Small Business Innovation Research (SBIR) program in the 2026 budget—one of the largest sources of early-stage technology commercialization capital—it has yet to be reauthorized and must be deployed by September 30 once approval occurs. SBIR accounts for about 3.2% of total federal funding available; other NIH mechanisms have also created more opportunities for translational, preclinical, and clinical research.
FreeMind works with hundreds of companies each year to maximize their chances in securing grants through targeted applications. Eligibility extends beyond U.S.-based firms: companies in Europe, Australia, Canada, Israel—and non-Chinese Asian pharmas like those from Japan and Korea—are already benefiting from NIH support via partnerships focused on identifying innovative technologies in Western markets.
However, it is becoming increasingly difficult for China-based or China-connected research entities to access these funds.
May-Ron advised that combining venture capital with nondilutive funding and family office investments can provide a unified financing strategy for early-stage biotech firms.
Ravi Kiron, managing director at Biopharma Strategy Advisors, observed increased interest from family offices seeking involvement in biotech without repeating mistakes made during what he called a previous “nuclear winter.” He said factors influencing their decisions include transparency around deal structure and return on investment as well as alignment with specific causes important to families—often related to rare diseases—which continues to shape investment trends.
Kiron added there is renewed interest in neuroscience investments thanks to advances in artificial intelligence (AI) and imaging technology that enable detailed brain mapping—a space BioSpace has reported continues strong innovation activity. Interest is also growing in platform technologies such as AI-driven computational biology because they promise reduced costs and faster timelines for drug development.
He emphasized that founders need both strong scientific foundations and compelling stories about how their drugs benefit patient populations while demonstrating capable teams and sound intellectual property strategies: “Ultimately, founders must have strong science and a compelling narrative about their drug benefit to patient populations and life improvement...while also demonstrating strong team dynamics, execution capability, capital management and a solid IP strategy.”
Unlike venture capital firms that rely heavily on junior analysts as gatekeepers, family offices often engage directly with potential investees.
Both Kiron and May-Ron agreed that successful early-stage investing requires leveraging multiple sources—including nondilutive financing alongside family offices or alternative financiers—to overcome current challenges facing biotech startups.
